You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lorlatinib

Showing 1 - 25 of 42
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • Lorlatinib
  • +2 more
  • (no location specified)
Jul 7, 2023

Stage III NSCLC, Surgery Trial in Guangzhou (Lorlatinib)

Not yet recruiting
  • Stage III NSCLC
  • Surgery
  • Lorlatinib
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Feb 21, 2023

ALK Positive NSCLC Trial in Guangzhou (Loratinib)

Recruiting
  • ALK Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Oct 19, 2023

Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Middletown, New Jersey
  • +5 more
Aug 17, 2023

Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers Trial in Tustin, Tampa, Saint Paul (Lorlatinib)

Recruiting
  • Moderate Hepatic Impairment
  • +2 more
  • Lorlatinib
  • Tustin, California
  • +2 more
Dec 7, 2022

Non-Small-Cell Lung Cancer, NSCLC Trial in Nagoya, Barcelona, Taipei (Lorlatinib)

Recruiting
  • Non-Small-Cell Lung Cancer
  • NSCLC
  • Lorlatinib
  • Nagoya, Aichi, Japan
  • +2 more
Jul 21, 2022

Pediatric Neuroblastoma Treated With Lorlatinib

Completed
  • Neuroblastoma
  • lorlatinib
  • Philadelphia, Pennsylvania
  • +10 more
Nov 17, 2022

Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)

Recruiting
  • Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
  • Lorlatinib
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's hospital
May 31, 2022

Advanced NSCLC Trial in India (Lorlatinib)

Completed
  • Advanced Non-Small Cell Lung Cancer
  • Lorlatinib
  • New Delhi, Delhi, India
  • +11 more
Sep 13, 2022

Non Small Cell Lung Cancer, CNS Progression Trial in Aurora (Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • CNS Progression
  • Temozolomide plus Osimertinib
  • Temozolomide plus Lorlatinib
  • Aurora, Colorado
    University of Colorado Hospital
May 12, 2022

Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

Recruiting
  • Nonsmall Cell Lung Cancer
  • Lorlatinib
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Lorlatinib
  • Aix-en-Provence, France
  • +38 more
Aug 9, 2022

Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • lorlatinib
  • +17 more
  • Oslo, Norway
    Pfizer Norway
Apr 17, 2023

Lorlatinib in ALK/ROS1 Metastatic NSCLC Compassionate Use

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Lorlatinib
  • Santiago De Compostela, A Coruña, Spain
  • +24 more
Jun 1, 2022

Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • Lorlatinib
  • Orange, California
  • +31 more
Dec 6, 2022

Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Lorlatinib
  • Angers, France
  • +31 more
Apr 12, 2022

Cancer, Advanced Solid Tumor Trial in Kettering (lorlatinib, encorafenib + binimetinib, talazoparib)

Recruiting
  • Cancer
  • Advanced Solid Tumor
  • lorlatinib
  • +4 more
  • Kettering, Ohio
    Kettering Health Network
Oct 14, 2022

Renal Impairment Trial in Anaheim, Saint Paul (Lorlatinib)

Completed
Has Results
  • Renal Impairment
  • Lorlatinib
  • Anaheim, California
  • +1 more
Feb 2, 2021

Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

Recruiting
  • Lung Cancer
  • +6 more
  • Lorlatinib
  • +3 more
  • Boston, Massachusetts
  • +1 more
Mar 7, 2021

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese

Completed
  • ALK-positive Non-small-cell Lung Cancer
  • Nagoya, Aichi, Japan
  • +15 more
Jan 31, 2022

NSCLC (NSCLC) Trial in Boston (Lorlatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Lorlatinib
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 7, 2021

NSCLC Trial in China (Lorlatinib)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Lorlatinib
  • Hefei, Anhui, China
  • +20 more
Sep 27, 2021

Solid Tumor Trial in United States (PF-07284892, lorlatinib, binimetinib)

Recruiting
  • Solid Tumor
  • Orange, California
  • +6 more
Feb 15, 2022